Related Experiment Video
Updated: Oct 8, 2026
Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds
Published on: July 16, 2018
[New strategies for the postsurgical treatment of malignant glioma]
Abstract:
Malignant gliomas are known for their intrinsic heterogeneity that contributes to tumour recurrence, despite aggressive multimodality therapy. New approaches of post surgical treatment are formulated, according to specific aspects of the biology of gliomas including angiogenesis, invasion, DNA-repair mechanisms, cell cycle regulation and apoptosis. Efforts are also done in order to define the use of currently available cytotoxic agents by combining them with so-called biologic modalities. Thus there has been a change in the concept of management of malignant gliomas focusing the aim in containing the tumour, rather than attempting a cure.
Insights
Malignant gliomas are complex tumors that often recur. New treatments focus on targeting specific biological aspects to manage, rather than cure, these challenging brain tumors.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Genetics
Background:
- Malignant gliomas exhibit significant intra-tumoral heterogeneity, a key factor in treatment resistance and recurrence.
- Despite aggressive multimodality therapies, complete eradication of malignant gliomas remains a significant challenge.
Discussion:
- Novel post-surgical treatment strategies are being developed, focusing on glioma biology such as angiogenesis, invasion, DNA repair, cell cycle regulation, and apoptosis.
- Current research explores combining established cytotoxic agents with novel biologic therapies.
Key Insights:
- Understanding glioma heterogeneity is crucial for developing effective therapeutic strategies.
- Targeting specific molecular pathways offers a promising avenue for managing malignant gliomas.
Outlook:
- The paradigm for malignant glioma management is shifting from curative attempts to long-term tumor containment.
- Future research will likely focus on personalized medicine approaches based on the specific biological profile of individual gliomas.
